SNHi, I am Savvy Niyogi.
I am a finance professional with 16 years of experience, split between investment banking and FP&A. For the last nine years, I have worked in FP&A, helping senior leaders at Xellia Pharmaceuticals, Novozymes and Better Energy make better decisions. Along the way, I have worked across pharma, biotech and renewables.
Before that, I spent several years in equity research, including sell-side coverage of chemicals and pharma at UBS in London.
Today I build AI-powered finance tools that turn numbers into decisions. Every dashboard on this site uses dummy data, but each one solves a real problem I have faced as a finance partner.
Intro video
01Experience
FP&A Manager, Xellia Pharmaceuticals A/S, Copenhagen. Dec 2024 to Oct 2026.
- Replaced fragmented reporting with one KPI framework and executive dashboards, adopted by the CFO, ELT and Board within 30 days.
- Built the Group Annual Planning Calendar across Finance, R&D and Global Production, Supply & Quality.
- Rolled out a balanced scorecard with finance teams in Hungary, Austria and Copenhagen.
Senior FP&A Manager, Better Energy A/S, Copenhagen. Dec 2023 to Nov 2024.
- Delivered a Deloitte-validated pre-IPO model in three months, covering 156 solar projects with NPV, IRR and sum-of-the-parts valuation.
- Ran scenarios on power prices, geography and project stage to guide capital allocation.
Business Finance Manager, Group FP&A, Novozymes A/S, Copenhagen. Oct 2017 to Nov 2023.
- Owned Group management reporting and rolling forecasts for six years, and led the monthly Pulse Check review with division heads, the CFO and ELT.
- Built NPV models across 40+ portfolio units for capital allocation.
- Implemented a reporting system that cut reporting man-hours by 20%.
Analyst, Hashemi Capital (Lighthouse Partners), London. Dec 2016 to Sep 2017.
- Pitched alpha ideas in Chemicals and Pharmaceuticals for a USD 16bn long/short fund.
Associate Director, Equity Research, UBS AG, London. Sep 2015 to Oct 2016.
- Lead analyst covering ten listed Chemicals and Pharma companies across Europe and Israel.
- Anti-consensus Buy call on Umicore delivered a c.7% stock move, cited by Bloomberg, Reuters and The Wall Street Journal.
Research Manager, Cognizant Technology Solutions, Hyderabad. Jul 2011 to Aug 2015.
- Embedded with the UBS Chemicals team, which led to a direct offer from UBS London.
02Education
- CFA Level I (passed), CFA Institute
- Post Graduate Diploma in Strategic Finance and Control, ICFAI, India
- Post Graduate Diploma in Business Management, ISMS Pune, India
- Bachelor of Commerce, Accountancy (Honours), Calcutta University
- AI for Financial Analysis, three certification courses, Corporate Finance Institute, 2026
- Certificate in Business Analysis (BCS), UK, and CISI Level 3 Certificates, UK
03Languages
English (fluent), Danish (intermediate, PD3), Hindi (native).